Literature DB >> 3494804

Alterations in plasma lipoproteins and apolipoproteins in experimental allergic encephalomyelitis.

V G Shore, M E Smith, V Perret, M A Laskaris.   

Abstract

Plasma lipoproteins were investigated during the active clinical phase of experimental allergic encephalomyelitis (EAE), a demyelinating disease of the central nervous system. Three groups of Lewis rats were compared: untreated controls, Freund's adjuvant-treated controls (FAC), and rats receiving one injection of myelin in Freund's adjuvant. After onset of clinical symptoms, 12 and 16 days after injection, there were higher concentrations of cholesterol and low and high density lipoproteins (LDL and HDL) in EAE plasma. The increase was due to apoE-containing HDL1 and HDL, according to density, particle size, and apolipoprotein compositions of isolated lipoproteins and immunoblots of whole plasmas after gradient gel electrophoresis. In EAE, the cholesterol-to-apoprotein ratio was increased and the low density lipoprotein distribution profile was shifted toward lower density. The Freund's adjuvant-treated control rats showed some changes qualitatively similar to those of EAE, albeit far smaller in magnitude. Changes in LDL in EAE might be related in part to lowered plasma very low density lipoproteins (VLDL); however, weight loss in control animals did not increase plasma cholesterol or apoE relative to apoA-I. Lesions in the central nervous system and/or activation of macrophages might be causally related to the large increase in plasma apoE. The major changes in apoE-containing lipoproteins are undoubtedly significant for the altered immune function in EAE.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3494804

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

Review 1.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

Review 2.  The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Hong-Liang Zhang; Jiang Wu; Jie Zhu
Journal:  Clin Dev Immunol       Date:  2010-05-31

3.  Comparison of serum apolipoprotein A-I between Chinese multiple sclerosis and other related autoimmune disease.

Authors:  Bin Zhang; ShuXiang Pu; BinMei Li; JianRui Ying; Xing Wang Song; Cong Gao
Journal:  Lipids Health Dis       Date:  2010-03-29       Impact factor: 3.876

Review 4.  Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis.

Authors:  Francisco J Quintana; Ada Yeste; Howard L Weiner; Ruxandra Covacu
Journal:  J Neuroimmunol       Date:  2012-05-12       Impact factor: 3.478

5.  Profile of Circulatory Metabolites in a Relapsing-remitting Animal Model of Multiple Sclerosis using Global Metabolomics.

Authors:  Ak Mangalam; Lm Poisson; E Nemutlu; I Datta; A Denic; P Dzeja; M Rodriguez; R Rattan; S Giri
Journal:  J Clin Cell Immunol       Date:  2013-06-30

Review 6.  Metabolic Dysfunction and Peroxisome Proliferator-Activated Receptors (PPAR) in Multiple Sclerosis.

Authors:  Véronique Ferret-Sena; Carlos Capela; Armando Sena
Journal:  Int J Mol Sci       Date:  2018-06-01       Impact factor: 5.923

Review 7.  Molecular profile of reactive astrocytes--implications for their role in neurologic disease.

Authors:  M Eddleston; L Mucke
Journal:  Neuroscience       Date:  1993-05       Impact factor: 3.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.